Objective To investigate the impact of the precision health management model on liver fibrosis, adipocytokines, and metabolic indicators in patients with non-alcoholic fatty liver disease (NAFLD).

Methods A total of 600 NAFLD patients were selected as study subjects and divided into conventional group and precision group according to different intervention methods, with 300 patients in each group. The conventional group received routine health management, while the precision group received intervention through the precision health management model. Comparisons were made between the two groups in terms of obesity indicatorswaist-to-hip ratio (WHR), body mass index (BMI), body fat rate (BFR), degree of obesity, fatty liver grading, liver stiffness measurement (LSM), and liver fibrosis indicators laminin (LN), type Ⅳ collagen (CⅣ), hyaluronic acid (HA), type Ⅲ procollagen (PCⅢ), hepatic adipocytokinesnuclear factor-κB (NF-κB), adiponectin (APN), irisin, tumor necrosis factor-α (TNF-α), and lipid metabolism indicatorstriglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC)levels.

Results After the intervention, the levels of WHR, BFR, BMI, degree of obesity, LSM, as well as LN, CⅣ, HA, PCⅢ, NF-κB, TNF-α, TG, LDL-C, and TC in both groups were lower than those before the intervention, and the precision group showed lower levels than the conventional group, with statistically significant differences (P < 0.05). After the intervention, the fatty liver grading in both groups was better than before intervention, and the precision group showed better fatty liver grading than the conventional group, with statistically significant differences (P < 0.05). After the intervention, the levels of APN, irisin, and HDL-C in both groups were higher than those before the intervention, and the precision group showed higher levels than the conventional group, with statistically significant differences (P < 0.05).

Conclusion The precision health management model can effectively improve the degree of obesity, fatty liver grading, and liver fibrosis status in NAFLD patients, reduce LSM, and regulate the levels of adipocytokines and lipid metabolism indicators, yielding significant effects.